View Document Preview and Link Document Date: 2013-10-25 08:10:13 Open Document File Size: 82,64 KB Share Result on Facebook
City London / / Continent Europe / / Country France / United Kingdom / / / Facility Canary Wharf / / IndustryTerm healthcare professionals / pharmaceutical forms / treatment of Raynaud’s syndrome / / MedicalCondition intermittent claudication / chronic pathological cognitive and neurosensorial impairment / Alzheimer’s disease / dementia / acute migraine / circulatory disorders / Raynaud’s syndrome / symptomatic peripheral arterial occlusive disease / spasms / sometimes fatal disease / peripheral arterial occlusive disease / heart valve fibrosis / Orthostatic hypotension / pain / migraine headaches / ergot poisoning / acute migraine headache / pulmonary and pleural fibrosis / migraine headache / fibrosis / / Organization French National Agency for the Safety of Medicine and Health Products / EMA’s Committee for Medicinal Products for Human Use / European Medicines Agency / European Commission / European Union / E-mail info@ema.europa.eu Website www.ema.europa.eu An / / Person Monika Benstetter / Martin Harvey / / / Position pharmacist / / PublishedMedium the CHMP review / / URL www.ema.europa.eu / / SocialTag 
Ergot derivatives_13.06_public health communication after re-examination for dihydroergotoxine